Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

NCT04652206 is registered in ClinicalTrials.gov with Scandion Oncology A/S as lead sponsor.

NCT NCT04652206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04652206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
Lead sponsor
Scandion Oncology A/S
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 27, 2020
Completion date
May 15, 2022
Enrollment
18 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

inoperable disease, localized pancreatic adenocarcinoma, locally advanced pancreatic adenocarcinoma, metastatic pancreatic adenocarcinoma